

A compartmentalized joint-on-chip to unravel cartilage-synovium crosstalk in osteoarthritis

Palma C.¹, Salehi S.², Moretti M.², Occhetta P.¹, Lopa S.², Rasponi M.¹


¹Department of Electronics, Information and Bioengineering, Politecnico di Milano, Italy; ²Cell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy

INTRODUCTION

Osteoarthritis (OA) is the most prevalent degenerative joint disorder, but no reversing therapies have been developed yet¹, due to the disease complexity and to the disease multifactorial aetiology². A gap of knowledge still exists on initial disease mechanisms, linked to the unavailability of reliable human preclinical in vitro OA models³. In this scenario, organs-on-chip are promising candidates to elucidate cause-effect relationship among players in early OA stages. To this end, we developed a compartmentalized joint-on-chip model for the co-culture of cartilage and synovium, aiming at evaluating the disruption of the physiological cross-talk between these tissues that contributes to the pathogenesis of OA⁴.

COMPARTMENTALIZED MICROFLUIDIC PLATFORM FOR CARTILAGE-SYNOVIUM CO-CULTURE


The microfluidic device (A) comprises a culture chamber layer consisting of two separate culture areas, intended for synovium and cartilage cultures, respectively, whose paracrine communication is controlled through normally closed curtain valves. An actuation layer allows to apply a mechanical compression to the cartilage compartment upon pressurization⁵. The platforms were fabricated in PDMS through soft lithography (B) and technically characterized to estimate cytokine diffusion from one compartment towards the other one, upon central valves opening (C).



SYNOVIUM MODEL

Human synovial fibroblasts (SFB) and macrophages (M0) were embedded in a mix of fibrin gel and collagen I (50/50 ratio v/v), with a total cell density of 25 M/ml (SFB/M0 ratio 50/50) and cultured for up to 7 days. Immunofluorescence stainings proved proper synthesis of collagen I and lubricin (A).


A protocol was established to induce M0 polarization towards pro-inflammatory state (M1): an inflammatory stimulus (TNF- α +IFN- γ) was administered for 3 days to M0 cultured in 2D, followed by 4 days without stimuli. As proven by flow cytometry (FACS), an increase in the expression of inflammatory markers (CD80, CD86) was detected at day 3 (B), and maintained until day 7 (C). The same protocol was applied to the 3D synovial model, confirming induction of an inflammatory phenotype on resident macrophages.



CARTILAGE MODEL


Human articular chondrocytes embedded in fibrin gel (50 M/ml) were cultured for two weeks in chondrogenic medium, and cartilage maturation was demonstrated by upregulation of COL2A1 and ACAN (A), and deposition of matrix rich in collagen (B).

A cyclical hyperphysiological compression (HPC) was applied for one week to induce a shift towards an OA phenotype⁵, as assessed through upregulation of cytokine IL8 and degrading enzyme MMP13 (C). Liquid chromatography-mass spectrometry (LC-MS) was performed on cell supernatant: differentially expressed proteins were identified, suggesting pathways possibly correlating with OA onset (D).



CO-CULTURE OF 3D SYNOVIAL AND CARTILAGE MODELS

An experimental set-up was optimized to co-culture cartilage and synovial microtissues in the platform, exploiting compartmentalization to comply with specific maturation timings.



DISCUSSION and CONCLUSIONS

The proposed device offers a solution to mature cartilage and synovial constructs in separated compartments, by enabling a temporal control over chambers communications. The platform is being currently used to assess whether mechanically-damaged cartilage triggers inflammatory changes in the synovium, and whether synovitis has a role on cartilage degradation, eventually allowing to understand which of the two tissues has a predominant role in early OA stages.

ACKNOWLEDGMENTS

This work was supported by Fondazione Cariplo-uKNEEque - Rif. 2018/0551 and OAonChip - Rif. 2021-1564 and has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 841975.

REFERENCES

- Martel-Pelletier et al, *Nat Rev Dis Prim*, 2, 16072 (2016)
- Lories et al, *Nat. Rev. Rheumatol.*, 7, 43-49 (2011)
- Bartolotti et al, *J. Clin. Med.*, 10, 1920 (2021)
- Chou et al, *Sci Rep*, 10, 10868 (2020)
- Occhetta et al, *Nat Biomed Eng*, 3, 545-557 (2019)